Clinical trials for Anal cancer

92 currently recruiting clinical trials
Phase 1 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT05614739
Cohortes A1 et C1
Locally Advanced Metastatic Metastatic Castration-resistant FGFR 1 2 3 or more
Systemic Treatment-Naive
Centre Léon Bérard (Lyon), Institut Bergonié (Bordeaux), Gustave Roussy (Villejuif)
Eli Lilly et compagnie
Phase 1 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT06179160 #2023-507091-47-00
Locally Advanced Metastatic KRAS G12D 1 2 3 or more
Systemic Treatment-Naive
Gustave Roussy (Villejuif), Centre Léon Bérard (Lyon), IUCT Oncopôle (Toulouse)
Incyte Corporation
Phase 1 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT06533059 #2024-515391-12-00
Locally Advanced Metastatic AKT 1 2 3 or more
BRAF KRAS G12C KRAS non G12C NRAS HRAS KRAS G12D Systemic Treatment-Naive
CGFL Dijon - Centre Régional De Lutte Contre Le Cancer Georges - François Leclerc (Dijon ), Centre François Baclesse (Caen ), Gustave Roussy (Villejuif), Institut de Cancérologie de l'Ouest - Site de Saint-Herblain (Saint-Herblain)
Alterome Therapeutics, Inc.
Phase 1 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT05216432
Cohortes monothérapies (tumeurs solides PIK3CA mutées)
Locally Advanced Metastatic PIK3CA 1 2 3 or more
Systemic Treatment-Naive
Centre Léon Bérard (Lyon), Gustave Roussy (Villejuif), Institut Bergonié (Bordeaux)
Relay Therapeutics, Inc.
Phase 1 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT06253871
HER2 Positive Locally Advanced Metastatic Metastatic Castration-resistant HER2 1 2 3 or more
Systemic Treatment-Naive
CGFL Dijon - Centre Régional De Lutte Contre Le Cancer Georges - François Leclerc (Dijon ), IUCT Oncopôle (Toulouse), Institut de Cancérologie de l'Ouest - Site de Saint-Herblain (Saint-Herblain)
Iambic Therapeutics, Inc
Phase 1 Breast cancer Lung cancer Prostate cancer Anal cancer Kidney cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT04064359
Cohortes A à D (Tumeurs solides CD205+)
Locally Advanced Metastatic 1 2 3 or more
Systemic Treatment-Naive
Centre Eugene Marquis (Rennes), Hôpital Saint-Joseph (Paris), Hôpital Saint Louis AP-HP (Paris), ICANS - Institut de cancérologie Strasbourg Europe (Strasbourg), Institut Paoli-Calmettes (Marseille)
Oxford BioTherapeutics Ltd
Phase 1
Hôpital Saint Louis AP-HP (Paris)